Skip to content
Open access

Structure optimization, synthesis, and activity evaluation of Cyclopropane or pyridine-2-ketone derivatives as C-MET inhibitors

2026 · Brazilian Journal of Pharmaceutical Sciences · 0 citations · 21 references

Abstract

A series of novel small-molecule inhibitors targeting c-Met was designed, synthesized, and optimized based on high-throughput virtual screening of the lead compounds BMS-777607 and 17b. Biological activity evaluation revealed that most compounds demonstrated significant antiproliferation activity against A549 and HepG2 tumor cell lines. Among these compounds, 10a exhibited the most potent kinase inhibitory activity (IC50 = 0.31 μM). Compound 10a demonstrated strong apoptosis-inducing ability in A549 cells (IC50 = 1.38 μM) while showing negligible antiproliferative effects on the human normal liver cell line Chang liver (CCL13). Further investigation of the antitumor mechanism revealed that compound 10a inhibited the synthesis of key proteins, including PCNA, Cyclin D1, procaspase 3, BCL-2, and mitochondrial Cyt c in A549 cells. Additionally, it promoted the expression of cleaved caspase 3, BAX, and cytoplasmic cytochrome c, while inducing cell cycle arrest at the G2/M phase. Molecular docking studies demonstrated that 10a exhibited strong binding affinity to the ATP-binding site of c-Met. These findings suggest that compound 10a represents a promising lead molecule for further development of antitumor drugs.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.